Background Currently there are no effective treatments for many neurodegenerative
diseases. Reliable biomarkers for identifying and stratifying these diseases will be important …

Background Alzheimer's disease (AD) is the leading cause of dementia affecting greater
than 26 million people worldwide. Although cerebrospinal fluid (CSF) levels of Aβ 42, tau …

Alzheimer's disease (AD) is the most common cause of dementia, characterized by
progressive cognitive decline. The main disease hallmarks include amyloid beta aggregates …

Altered levels of cerebrospinal fluid (CSF) peptides related to Alzheimer's disease (AD) are
associated with pathologic AD diagnosis, although cognitively normal subjects can also …

The pathology of Alzheimer's disease (AD) begins years prior to clinical diagnosis. The
development of antecedent biomarkers that indicate the presence of AD pathology and …

Background Diagnosis of dementia with Lewy bodies (DLB) is challenging, largely due to a
lack of diagnostic tools. Cerebrospinal fluid (CSF) biomarkers have been proven useful in …

Biomarkers are needed to assist in the diagnosis and medical management of various
neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD) …

Alzheimer's disease (AD) is the most common cause of dementia. Biomarkers are required
to identify individuals in the preclinical phase, explain phenotypic diversity, measure …

To date, the development of disease-modifying therapies for Alzheimer's disease (AD) has
largely focused on the removal of amyloid beta Aβ fragments from the CNS. Proteomic …

Background Several studies suggest that pathological changes in Alzheimer's disease (AD)
brain begin around 10–20 years before the onset of cognitive impairment. Biomarkers that …